Evidence map›Paper›PMID 28580765›Full record

ArticleJournal of biomedical materials research. Part B, Applied biomaterials2018

In vitro evaluation of a basic fibroblast growth factor-containing hydrogel toward vocal fold lamina propria scar treatment.

Josh D Erndt-Marino, Andrea C Jimenez-Vergara, Patricia Diaz-Rodriguez, Jonathan Kulwatno, Juan Felipe Diaz-Quiroz, Susan Thibeault, Mariah S Hahn

Abstract read
In one paragraph

Article in Journal of biomedical materials research. Part B, Applied biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. The life-cycle and restoration of the human vocal fold.Laryngoscope investigative otolaryngology · 2023
    Review
  6. Article
  7. Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature.Journal of molecular medicine (Berlin, Germany) · 2022
    Review
  8. Bioreactors for Vocal Fold Tissue Engineering.Tissue engineering. Part B, Reviews · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. In vitro evaluation of anti-fibrotic effects of select cytokines for vocal fold scar treatment.Journal of biomedical materials research. Part B, Applied biomaterials · 2019
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Josh D Erndt-MarinoDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York.
Andrea C Jimenez-VergaraDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York.
Patricia Diaz-RodriguezDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York.
Jonathan KulwatnoDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York.
Juan Felipe Diaz-QuirozDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York.
Susan ThibeaultDepartment of Surgery, Division of Otolaryngology-Head & Neck Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Mariah S HahnDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York.
Rensselaer Polytechnic Institute · USUniversity of Wisconsin–Madison · US

Funding

Macrophage And Fibroblast Modulation Toward Chronic Vocal Fold Scar RestorationR01DC013508 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI HAHN, MARIAH S, THIBEAULT, SUSAN LYNN · 2014 to 2018
$2.5M
NIDCD NIH HHS R01 DC013508
6 · The paper itself

Abstract

Scarring of the vocal fold lamina propria can lead to debilitating voice disorders that can significantly impair quality of life. The reduced pliability of the scar tissue-which diminishes proper vocal fold vibratory efficiency-results in part from abnormal extracellular matrix (ECM) deposition by vocal fold fibroblasts (VFF) that have taken on a fibrotic phenotype. To address this issue, bioactive materials containing cytokines and/or growth factors may provide a platform to transition fibrotic VFF within the scarred tissue toward an anti-fibrotic phenotype, thereby improving the quality of ECM within the scar tissue. However, for such an approach to be most effective, the acute host response resulting from biomaterial insertion/injection likely also needs to be considered. The goal of the present work was to evaluate the anti-fibrotic and anti-inflammatory capacity of an injectable hydrogel containing tethered basic fibroblast growth factor (bFGF) in the dual context of scar and biomaterial-induced acute inflammation. An in vitro co-culture system was utilized containing both activated, fibrotic VFF and activated, pro-inflammatory macrophages (MΦ) within a 3D poly(ethylene glycol) diacrylate (PEGDA) hydrogel containing tethered bFGF. Following 72 h of culture, alterations in VFF and macrophage phenotype were evaluated relative to mono-culture and co-culture controls. In our co-culture system, bFGF reduced the production of fibrotic markers collagen type I, α smooth muscle actin, and biglycan by activated VFF and promoted wound-healing/anti-inflammatory marker expression in activated MΦ. Cumulatively, these data indicate that bFGF-containing hydrogels warrant further investigation for the treatment of vocal fold lamina propria scar. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1258-1267, 2018.

Indexed as

HydrogelsAnimalsAnti-Inflammatory Agents, Non-SteroidalCells, CulturedCicatrixCoculture TechniquesCytokinesExtracellular MatrixFibroblast Growth Factor 2FibroblastsFibrosisHumansMacrophage ActivationMiceRAW 264.7 CellsRheologyAnti-Inflammatory Agents, Non-SteroidalCytokinesFibroblast Growth Factor 2Hydrogels3D cell culturebasic fibroblast growth factorimmunomodulationvocal fold lamina propriavocal fold scar

Identifiers

PMID28580765
PMCPMC5862030
OpenAlexW2621000300

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.